Click for best price
Urological Cancer Therapeutics Drugs Market Size, Share 2022
Global Urological Cancer Therapeutics Drugs Market is estimated to reach $48.6 billion by 2025 Says, .Now a days urological cancers became very common worldwide and causing higher mortality rates. Specially in the case of kidney cancers, that illustrates the new therapeutic targets. Urological cancers accounts for approximately 20% of global cancer prevalence. This type of cancer affects the urinary tract of male and female and the male reproductive organs.
This report contains market size and forecasts of Urological Cancer Therapeutics Drugs in global, including the following market information:
Global Urological Cancer Therapeutics Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Urological Cancer Therapeutics Drugs Market Sales, 2017-2022, 2023-2028, (K MT)
Global top five Urological Cancer Therapeutics Drugs companies in 2021 (%)
The global Urological Cancer Therapeutics Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Xofigo (radium Ra 223 dichloride) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Urological Cancer Therapeutics Drugs include Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation and Dendreon Corporation, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Urological Cancer Therapeutics Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Urological Cancer Therapeutics Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Urological Cancer Therapeutics Drugs Market Segment Percentages, by Type, 2021 (%)
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)
Global Urological Cancer Therapeutics Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Urological Cancer Therapeutics Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital
Medical Research Laboratory
Others
Global Urological Cancer Therapeutics Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Urological Cancer Therapeutics Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Urological Cancer Therapeutics Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Urological Cancer Therapeutics Drugs revenues share in global market, 2021 (%)
Key companies Urological Cancer Therapeutics Drugs sales in global market, 2017-2022 (Estimated), (K MT)
Key companies Urological Cancer Therapeutics Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
| Report Attributes |
Report Details |
| Report Title |
Urological Cancer Therapeutics Drugs Market - Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
114 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Urological Cancer Therapeutics Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Urological Cancer Therapeutics Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Urological Cancer Therapeutics Drugs Overall Market Size
2.1 Global Urological Cancer Therapeutics Drugs Market Size: 2021 VS 2028
2.2 Global Urological Cancer Therapeutics Drugs Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Urological Cancer Therapeutics Drugs Sales: 2017-2028
3 Company Landscape
3.1 Top Urological Cancer Therapeutics Drugs Players in Global Market
3.2 Top Global Urological Cancer Therapeutics Drugs Companies Ranked by Revenue
3.3 Global Urological Cancer Therapeutics Drugs Revenue by Companies
3.4 Global Urological Cancer Therapeutics Drugs Sales by Companies
3.5 Global Urological Cancer Therapeutics Drugs Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Urological Cancer Therapeutics Drugs Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Urological Cancer Therapeutics Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Urological Cancer Therapeutics Drugs Players in Global Market
3.8.1 List of Global Tier 1 Urological Cancer Therapeutics Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Urological Cancer Therapeutics Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Urological Cancer Therapeutics Drugs Market Size Markets, 2021 & 2028
4.1.2 Xofigo (radium Ra 223 dichloride)
4.1.3 Jevtana (cabazitaxel)
4.1.4 Inlyta (axitinib)
4.1.5 Votrient (pazopanib hydrochloride)
4.1.6 Sutent (sunitinib malate)
4.1.7 Zytiga (abiraterone acetate)
4.1.8 Xtandi (enzalutamide)
4.1.9 Opdivo (nivolumab)
4.1.10 Provenge (sipuleucel-T)
4.2 By Type - Global Urological Cancer Therapeutics Drugs Revenue & Forecasts
4.2.1 By Type - Global Urological Cancer Therapeutics Drugs Revenue, 2017-2022
4.2.2 By Type - Global Urological Cancer Therapeutics Drugs Revenue, 2023-2028
4.2.3 By Type - Global Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028
4.3 By Type - Global Urological Cancer Therapeutics Drugs Sales & Forecasts
4.3.1 By Type - Global Urological Cancer Therapeutics Drugs Sales, 2017-2022
4.3.2 By Type - Global Urological Cancer Therapeutics Drugs Sales, 2023-2028
4.3.3 By Type - Global Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028
4.4 By Type - Global Urological Cancer Therapeutics Drugs Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Urological Cancer Therapeutics Drugs Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Medical Research Laboratory
5.1.4 Others
5.2 By Application - Global Urological Cancer Therapeutics Drugs Revenue & Forecasts
5.2.1 By Application - Global Urological Cancer Therapeutics Drugs Revenue, 2017-2022
5.2.2 By Application - Global Urological Cancer Therapeutics Drugs Revenue, 2023-2028
5.2.3 By Application - Global Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028
5.3 By Application - Global Urological Cancer Therapeutics Drugs Sales & Forecasts
5.3.1 By Application - Global Urological Cancer Therapeutics Drugs Sales, 2017-2022
5.3.2 By Application - Global Urological Cancer Therapeutics Drugs Sales, 2023-2028
5.3.3 By Application - Global Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028
5.4 By Application - Global Urological Cancer Therapeutics Drugs Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Urological Cancer Therapeutics Drugs Market Size, 2021 & 2028
6.2 By Region - Global Urological Cancer Therapeutics Drugs Revenue & Forecasts
6.2.1 By Region - Global Urological Cancer Therapeutics Drugs Revenue, 2017-2022
6.2.2 By Region - Global Urological Cancer Therapeutics Drugs Revenue, 2023-2028
6.2.3 By Region - Global Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028
6.3 By Region - Global Urological Cancer Therapeutics Drugs Sales & Forecasts
6.3.1 By Region - Global Urological Cancer Therapeutics Drugs Sales, 2017-2022
6.3.2 By Region - Global Urological Cancer Therapeutics Drugs Sales, 2023-2028
6.3.3 By Region - Global Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Urological Cancer Therapeutics Drugs Revenue, 2017-2028
6.4.2 By Country - North America Urological Cancer Therapeutics Drugs Sales, 2017-2028
6.4.3 US Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.4.4 Canada Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.4.5 Mexico Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Urological Cancer Therapeutics Drugs Revenue, 2017-2028
6.5.2 By Country - Europe Urological Cancer Therapeutics Drugs Sales, 2017-2028
6.5.3 Germany Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.5.4 France Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.5.5 U.K. Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.5.6 Italy Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.5.7 Russia Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.5.8 Nordic Countries Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.5.9 Benelux Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Urological Cancer Therapeutics Drugs Revenue, 2017-2028
6.6.2 By Region - Asia Urological Cancer Therapeutics Drugs Sales, 2017-2028
6.6.3 China Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.6.4 Japan Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.6.5 South Korea Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.6.6 Southeast Asia Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.6.7 India Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Urological Cancer Therapeutics Drugs Revenue, 2017-2028
6.7.2 By Country - South America Urological Cancer Therapeutics Drugs Sales, 2017-2028
6.7.3 Brazil Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.7.4 Argentina Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Sales, 2017-2028
6.8.3 Turkey Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.8.4 Israel Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.8.5 Saudi Arabia Urological Cancer Therapeutics Drugs Market Size, 2017-2028
6.8.6 UAE Urological Cancer Therapeutics Drugs Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Novartis
7.1.1 Novartis Corporate Summary
7.1.2 Novartis Business Overview
7.1.3 Novartis Urological Cancer Therapeutics Drugs Major Product Offerings
7.1.4 Novartis Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
7.1.5 Novartis Key News
7.2 Pfizer
7.2.1 Pfizer Corporate Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Urological Cancer Therapeutics Drugs Major Product Offerings
7.2.4 Pfizer Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
7.2.5 Pfizer Key News
7.3 Johnson & Johnson
7.3.1 Johnson & Johnson Corporate Summary
7.3.2 Johnson & Johnson Business Overview
7.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Major Product Offerings
7.3.4 Johnson & Johnson Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
7.3.5 Johnson & Johnson Key News
7.4 AstraZeneca
7.4.1 AstraZeneca Corporate Summary
7.4.2 AstraZeneca Business Overview
7.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Major Product Offerings
7.4.4 AstraZeneca Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
7.4.5 AstraZeneca Key News
7.5 Astellas
7.5.1 Astellas Corporate Summary
7.5.2 Astellas Business Overview
7.5.3 Astellas Urological Cancer Therapeutics Drugs Major Product Offerings
7.5.4 Astellas Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
7.5.5 Astellas Key News
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Corporate Summary
7.6.2 Bristol-Myers Squibb Business Overview
7.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Major Product Offerings
7.6.4 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
7.6.5 Bristol-Myers Squibb Key News
7.7 Abbott Laboratories
7.7.1 Abbott Laboratories Corporate Summary
7.7.2 Abbott Laboratories Business Overview
7.7.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Major Product Offerings
7.7.4 Abbott Laboratories Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
7.7.5 Abbott Laboratories Key News
7.8 Celgene Corporation
7.8.1 Celgene Corporation Corporate Summary
7.8.2 Celgene Corporation Business Overview
7.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Major Product Offerings
7.8.4 Celgene Corporation Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
7.8.5 Celgene Corporation Key News
7.9 Dendreon Corporation
7.9.1 Dendreon Corporation Corporate Summary
7.9.2 Dendreon Corporation Business Overview
7.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Major Product Offerings
7.9.4 Dendreon Corporation Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
7.9.5 Dendreon Corporation Key News
7.10 Ferring Pharmaceuticals
7.10.1 Ferring Pharmaceuticals Corporate Summary
7.10.2 Ferring Pharmaceuticals Business Overview
7.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Major Product Offerings
7.10.4 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
7.10.5 Ferring Pharmaceuticals Key News
7.11 GlaxoSmithKline plc
7.11.1 GlaxoSmithKline plc Corporate Summary
7.11.2 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Business Overview
7.11.3 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Major Product Offerings
7.11.4 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
7.11.5 GlaxoSmithKline plc Key News
7.12 Indevus Pharmaceuticals Inc
7.12.1 Indevus Pharmaceuticals Inc Corporate Summary
7.12.2 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Business Overview
7.12.3 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Major Product Offerings
7.12.4 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
7.12.5 Indevus Pharmaceuticals Inc Key News
7.13 Ipsen
7.13.1 Ipsen Corporate Summary
7.13.2 Ipsen Urological Cancer Therapeutics Drugs Business Overview
7.13.3 Ipsen Urological Cancer Therapeutics Drugs Major Product Offerings
7.13.4 Ipsen Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
7.13.5 Ipsen Key News
7.14 Roche Healthcare
7.14.1 Roche Healthcare Corporate Summary
7.14.2 Roche Healthcare Business Overview
7.14.3 Roche Healthcare Urological Cancer Therapeutics Drugs Major Product Offerings
7.14.4 Roche Healthcare Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
7.14.5 Roche Healthcare Key News
7.15 Sanofi S.A.
7.15.1 Sanofi S.A. Corporate Summary
7.15.2 Sanofi S.A. Business Overview
7.15.3 Sanofi S.A. Urological Cancer Therapeutics Drugs Major Product Offerings
7.15.4 Sanofi S.A. Urological Cancer Therapeutics Drugs Sales and Revenue in Global (2017-2022)
7.15.5 Sanofi S.A. Key News
8 Global Urological Cancer Therapeutics Drugs Production Capacity, Analysis
8.1 Global Urological Cancer Therapeutics Drugs Production Capacity, 2017-2028
8.2 Urological Cancer Therapeutics Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Urological Cancer Therapeutics Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Urological Cancer Therapeutics Drugs Supply Chain Analysis
10.1 Urological Cancer Therapeutics Drugs Industry Value Chain
10.2 Urological Cancer Therapeutics Drugs Upstream Market
10.3 Urological Cancer Therapeutics Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Urological Cancer Therapeutics Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Urological Cancer Therapeutics Drugs in Global Market
Table 2. Top Urological Cancer Therapeutics Drugs Players in Global Market, Ranking by Revenue (2021)
Table 3. Global Urological Cancer Therapeutics Drugs Revenue by Companies, (US$, Mn), 2017-2022
Table 4. Global Urological Cancer Therapeutics Drugs Revenue Share by Companies, 2017-2022
Table 5. Global Urological Cancer Therapeutics Drugs Sales by Companies, (K MT), 2017-2022
Table 6. Global Urological Cancer Therapeutics Drugs Sales Share by Companies, 2017-2022
Table 7. Key Manufacturers Urological Cancer Therapeutics Drugs Price (2017-2022) & (USD/MT)
Table 8. Global Manufacturers Urological Cancer Therapeutics Drugs Product Type
Table 9. List of Global Tier 1 Urological Cancer Therapeutics Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Urological Cancer Therapeutics Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Global Urological Cancer Therapeutics Drugs Revenue (US$, Mn), 2017-2022
Table 13. By Type - Global Urological Cancer Therapeutics Drugs Revenue (US$, Mn), 2023-2028
Table 14. By Type - Global Urological Cancer Therapeutics Drugs Sales (K MT), 2017-2022
Table 15. By Type - Global Urological Cancer Therapeutics Drugs Sales (K MT), 2023-2028
Table 16. By Application ? Global Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2021 & 2028
Table 17. By Application - Global Urological Cancer Therapeutics Drugs Revenue (US$, Mn), 2017-2022
Table 18. By Application - Global Urological Cancer Therapeutics Drugs Revenue (US$, Mn), 2023-2028
Table 19. By Application - Global Urological Cancer Therapeutics Drugs Sales (K MT), 2017-2022
Table 20. By Application - Global Urological Cancer Therapeutics Drugs Sales (K MT), 2023-2028
Table 21. By Region ? Global Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2021 VS 2028
Table 22. By Region - Global Urological Cancer Therapeutics Drugs Revenue (US$, Mn), 2017-2022
Table 23. By Region - Global Urological Cancer Therapeutics Drugs Revenue (US$, Mn), 2023-2028
Table 24. By Region - Global Urological Cancer Therapeutics Drugs Sales (K MT), 2017-2022
Table 25. By Region - Global Urological Cancer Therapeutics Drugs Sales (K MT), 2023-2028
Table 26. By Country - North America Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2022
Table 27. By Country - North America Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2023-2028
Table 28. By Country - North America Urological Cancer Therapeutics Drugs Sales, (K MT), 2017-2022
Table 29. By Country - North America Urological Cancer Therapeutics Drugs Sales, (K MT), 2023-2028
Table 30. By Country - Europe Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2022
Table 31. By Country - Europe Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2023-2028
Table 32. By Country - Europe Urological Cancer Therapeutics Drugs Sales, (K MT), 2017-2022
Table 33. By Country - Europe Urological Cancer Therapeutics Drugs Sales, (K MT), 2023-2028
Table 34. By Region - Asia Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2022
Table 35. By Region - Asia Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2023-2028
Table 36. By Region - Asia Urological Cancer Therapeutics Drugs Sales, (K MT), 2017-2022
Table 37. By Region - Asia Urological Cancer Therapeutics Drugs Sales, (K MT), 2023-2028
Table 38. By Country - South America Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2022
Table 39. By Country - South America Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2023-2028
Table 40. By Country - South America Urological Cancer Therapeutics Drugs Sales, (K MT), 2017-2022
Table 41. By Country - South America Urological Cancer Therapeutics Drugs Sales, (K MT), 2023-2028
Table 42. By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2022
Table 43. By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2023-2028
Table 44. By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Sales, (K MT), 2017-2022
Table 45. By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Sales, (K MT), 2023-2028
Table 46. Novartis Corporate Summary
Table 47. Novartis Urological Cancer Therapeutics Drugs Product Offerings
Table 48. Novartis Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2017-2022)
Table 49. Pfizer Corporate Summary
Table 50. Pfizer Urological Cancer Therapeutics Drugs Product Offerings
Table 51. Pfizer Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2017-2022)
Table 52. Johnson & Johnson Corporate Summary
Table 53. Johnson & Johnson Urological Cancer Therapeutics Drugs Product Offerings
Table 54. Johnson & Johnson Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2017-2022)
Table 55. AstraZeneca Corporate Summary
Table 56. AstraZeneca Urological Cancer Therapeutics Drugs Product Offerings
Table 57. AstraZeneca Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2017-2022)
Table 58. Astellas Corporate Summary
Table 59. Astellas Urological Cancer Therapeutics Drugs Product Offerings
Table 60. Astellas Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2017-2022)
Table 61. Bristol-Myers Squibb Corporate Summary
Table 62. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Product Offerings
Table 63. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2017-2022)
Table 64. Abbott Laboratories Corporate Summary
Table 65. Abbott Laboratories Urological Cancer Therapeutics Drugs Product Offerings
Table 66. Abbott Laboratories Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2017-2022)
Table 67. Celgene Corporation Corporate Summary
Table 68. Celgene Corporation Urological Cancer Therapeutics Drugs Product Offerings
Table 69. Celgene Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2017-2022)
Table 70. Dendreon Corporation Corporate Summary
Table 71. Dendreon Corporation Urological Cancer Therapeutics Drugs Product Offerings
Table 72. Dendreon Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2017-2022)
Table 73. Ferring Pharmaceuticals Corporate Summary
Table 74. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Product Offerings
Table 75. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2017-2022)
Table 76. GlaxoSmithKline plc Corporate Summary
Table 77. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Product Offerings
Table 78. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2017-2022)
Table 79. Indevus Pharmaceuticals Inc Corporate Summary
Table 80. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Product Offerings
Table 81. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2017-2022)
Table 82. Ipsen Corporate Summary
Table 83. Ipsen Urological Cancer Therapeutics Drugs Product Offerings
Table 84. Ipsen Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2017-2022)
Table 85. Roche Healthcare Corporate Summary
Table 86. Roche Healthcare Urological Cancer Therapeutics Drugs Product Offerings
Table 87. Roche Healthcare Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2017-2022)
Table 88. Sanofi S.A. Corporate Summary
Table 89. Sanofi S.A. Urological Cancer Therapeutics Drugs Product Offerings
Table 90. Sanofi S.A. Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$, Mn) and Average Price (USD/MT) (2017-2022)
Table 91. Urological Cancer Therapeutics Drugs Production Capacity (K MT) of Key Manufacturers in Global Market, 2020-2022 (K MT)
Table 92. Global Urological Cancer Therapeutics Drugs Capacity Market Share of Key Manufacturers, 2020-2022
Table 93. Global Urological Cancer Therapeutics Drugs Production by Region, 2017-2022 (K MT)
Table 94. Global Urological Cancer Therapeutics Drugs Production by Region, 2023-2028 (K MT)
Table 95. Urological Cancer Therapeutics Drugs Market Opportunities & Trends in Global Market
Table 96. Urological Cancer Therapeutics Drugs Market Drivers in Global Market
Table 97. Urological Cancer Therapeutics Drugs Market Restraints in Global Market
Table 98. Urological Cancer Therapeutics Drugs Raw Materials
Table 99. Urological Cancer Therapeutics Drugs Raw Materials Suppliers in Global Market
Table 100. Typical Urological Cancer Therapeutics Drugs Downstream
Table 101. Urological Cancer Therapeutics Drugs Downstream Clients in Global Market
Table 102. Urological Cancer Therapeutics Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Urological Cancer Therapeutics Drugs Segment by Type
Figure 2. Urological Cancer Therapeutics Drugs Segment by Application
Figure 3. Global Urological Cancer Therapeutics Drugs Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Urological Cancer Therapeutics Drugs Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Urological Cancer Therapeutics Drugs Revenue, 2017-2028 (US$, Mn)
Figure 7. Urological Cancer Therapeutics Drugs Sales in Global Market: 2017-2028 (K MT)
Figure 8. The Top 3 and 5 Players Market Share by Urological Cancer Therapeutics Drugs Revenue in 2021
Figure 9. By Type - Global Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028
Figure 10. By Type - Global Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028
Figure 11. By Type - Global Urological Cancer Therapeutics Drugs Price (USD/MT), 2017-2028
Figure 12. By Application - Global Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028
Figure 13. By Application - Global Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028
Figure 14. By Application - Global Urological Cancer Therapeutics Drugs Price (USD/MT), 2017-2028
Figure 15. By Region - Global Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028
Figure 16. By Region - Global Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028
Figure 17. By Country - North America Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028
Figure 18. By Country - North America Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028
Figure 19. US Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 20. Canada Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 21. Mexico Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 22. By Country - Europe Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028
Figure 23. By Country - Europe Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028
Figure 24. Germany Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 25. France Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 26. U.K. Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 27. Italy Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 28. Russia Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 29. Nordic Countries Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 30. Benelux Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 31. By Region - Asia Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028
Figure 32. By Region - Asia Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028
Figure 33. China Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 34. Japan Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 35. South Korea Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 36. Southeast Asia Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 37. India Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 38. By Country - South America Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028
Figure 39. By Country - South America Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028
Figure 40. Brazil Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 41. Argentina Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 42. By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Revenue Market Share, 2017-2028
Figure 43. By Country - Middle East & Africa Urological Cancer Therapeutics Drugs Sales Market Share, 2017-2028
Figure 44. Turkey Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 45. Israel Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 46. Saudi Arabia Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 47. UAE Urological Cancer Therapeutics Drugs Revenue, (US$, Mn), 2017-2028
Figure 48. Global Urological Cancer Therapeutics Drugs Production Capacity (K MT), 2017-2028
Figure 49. The Percentage of Production Urological Cancer Therapeutics Drugs by Region, 2021 VS 2028
Figure 50. Urological Cancer Therapeutics Drugs Industry Value Chain
Figure 51. Marketing Channels
